文献速递泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗

前列腺癌合并炎症性肠病患者放射治疗的安全性:一项系统综述

Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review.
PubMed 文献 · Pract Radiat Oncol · 2023-04-24

该系统综述纳入12项回顾性研究共194例前列腺癌合并炎症性肠病(IBD)患者,评估盆腔放疗后胃肠道毒性。晚期3级及以上胃肠道毒性发生率在除1项外的所有研究中均低于5%,粗合并急性与晚期2级及以上事件率分别为15.3%和11.3%;作者认为3级及以上毒性发生率低,但需告知低级别毒性可能,活动性IBD等人群代表性不足。

要点

  • 12项回顾性研究共194例,晚期3级及以上胃肠道毒性在除1项外所有研究中低于5%。
  • 粗合并急性与晚期2级及以上胃肠道事件率分别为15.3%和11.3%。
  • 活动性IBD、接受盆腔放疗及既往腹部盆腔手术者代表性不足,结论不能外推。

核心结论

  • 前列腺癌合并IBD患者接受放疗似乎与较低的3级及以上胃肠道毒性发生率相关,但须告知患者低级别毒性可能。
  • 数据不能外推至活动性IBD、接受盆腔放疗及既往腹部盆腔手术等代表性不足的亚组,建议对高危病例个体化决策。

研究设计与样本

  • 遵循PRISMA的系统检索,检索PubMed/Embase,纳入报告前列腺癌合并IBD患者放疗后胃肠道毒性的原始研究。
  • 因人群、随访和毒性报告异质性大,未行正式Meta分析,仅总结各研究数据并计算粗合并率。
  • 共纳入12项回顾性研究、194例患者:5项以低剂量率近距离放疗单药为主,1项以高剂量率近距离放疗单药为主,3项外照射(三维适形或调强放疗)联合低剂量率近距离放疗,1项调强放疗联合高剂量率近距离放疗,2项立体定向放疗。

主要发现

  • 除1项研究外,所有研究中晚期3级及以上胃肠道毒性发生率均低于5%。
  • 粗合并急性2级及以上胃肠道事件率为15.3%(n=27/177例可评估患者;范围0%-100%)。
  • 粗合并晚期2级及以上胃肠道事件率为11.3%(n=20/177例可评估患者;范围0%-38.5%)。
  • 粗合并急性3级及以上胃肠道事件率为3.4%(6例;范围0%-23%)。
  • 粗合并晚期3级及以上胃肠道事件率为2.3%(4例;范围0%-15%)。

临床怎么用

  • 作者认为前列腺癌合并IBD患者放疗与低3级及以上胃肠道毒性相关,但须告知低级别毒性可能。
  • 作者建议对活动性IBD、接受盆腔放疗及既往腹部盆腔手术等高危病例个体化决策。
  • 作者建议考虑多种策略以降低该易感人群的毒性概率,包括仔细筛选患者、尽量减少 elective(淋巴结)治疗体积、使用直肠保护技术以及采用当代放疗先进技术以减少胃肠道危及器官受照(如调强放疗、基于磁共振成像的靶区勾画和高质量每日图像引导)。

局限性

  • 患者人群、随访和毒性报告实践存在显著异质性,妨碍了正式Meta分析。
  • 活动性IBD患者、接受盆腔放疗患者及既往腹部盆腔手术患者在各研究中代表性不足。
  • 数据不能外推至上述代表性不足的亚组人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Inflammatory bowel disease (IBD) has historically been considered a relative contraindication for pelvic radiation therapy (RT). To date, no systematic review has summarized the toxicity profile of RT for patients with prostate cancer and comorbid IBD. METHODS AND MATERIALS: A PRISMA-guided systematic search was conducted on PubMed/Embase for original investigations that reported gastrointestinal (GI; rectal/bowel) toxicity in patients with IBD undergoing RT for prostate cancer. The substantial heterogeneity in patient population, follow-up, and toxicity reporting practices precluded a formal meta-analysis; however, a summary of the individual study-level data and crude pooled rates was described. RESULTS: Twelve retrospective studies with 194 patients were included: 5 examined predominantly low-dose-rate brachytherapy (BT) monotherapy, 1 predominantly high-dose-rate BT monotherapy, 3 mixed external beam RT (3-dimensional conformal or intensity modulated RT [IMRT]) + low-dose-rate BT, 1 IMRT + high-dose-rate BT, and 2 stereotactic RT. Among these studies, patients with active IBD, patients receiving pelvic RT, and patients with prior abdominopelvic surgery were underrepresented. In all but 1 publication, the rate of late grade 3+ GI toxicities was <5%. The crude pooled rate of acute and late grade 2+ GI events was 15.3% (n = 27/177 evaluable patients; range, 0%-100%) and 11.3% (n = 20/177 evaluable patients; range, 0%-38.5%), respectively. Crude rates of acute and late grade 3+ GI events were 3.4% (6 cases; range, 0%-23%) and 2.3% (4 cases; range, 0%-15%). CONCLUSIONS: Prostate RT in patients with comorbid IBD appears to be associated with low rates of grade 3+ GI toxicity; however, patients must be counseled regarding the possibility for lower-grade toxicities. These data cannot be generalized to the underrepresented subpopulations mentioned above, and individualize decision-making is recommended for those high-risk cases. Several strategies should be considered to minimize the probability of toxicity in this susceptible population, including careful patient selection, minimizing elective (nodal) treatment volumes, using rectal sparing techniques, and employing contemporary RT advancements to minimize exposure to GI organs at risk (eg, IMRT, magnetic resonance imaging-based target delineation, and high-quality daily image guidance).

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Trotta M, Patel KR, Singh S, et al. Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review. Pract Radiat Oncol. 2023. PMID: 37100389. doi:10.1016/j.prro.2023.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。